Roche Holding AG (RHHBF)
OTCMKTS
· Delayed Price · Currency is USD
347.30
0.00 (0.00%)
Apr 17, 2025, 4:00 PM EDT
Roche Holding AG Revenue
In the year 2024, Roche Holding AG had annual revenue of 62.40B CHF with 3.23% growth. Roche Holding AG had revenue of 31.64B in the half year ending December 31, 2024, a decrease of -0.86%.
Revenue
62.40B CHF
Revenue Growth
+3.23%
P/S Ratio
3.63
Revenue / Employee
604.32K CHF
Employees
103,249
Market Cap
250.02B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SS Innovations International | 20.65M |
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 200.90M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 210.49M |
| American Oncology Network | 1.76B |
Roche Holding AG News
- 3 days ago - Oak Hill Bio Enters into Exclusive License Agreement with Roche to Obtain Global Rights for a Phase 3-Ready, Potential Best-in-Class Treatment for Individuals with Angelman Syndrome - Business Wire
- 4 days ago - European Commission approves Roche's Columvi as the first bispecific antibody for diffuse large ... - GuruFocus
- 4 days ago - European Commission approves Roche's Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy - GlobeNewsWire
- 7 days ago - Roche: Forget Tariffs And Focus On The Positives -- There Are Many - Seeking Alpha
- 7 days ago - Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight - Benzinga
- 7 days ago - Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages - CNBC
- 7 days ago - Zealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With Roche - WSJ
- 7 days ago - Biocon shares rise over 3% as USFDA approves bevacizumab biosimilar Jobevne™ for cancer treatment - Business Upturn